使用导电聚合物/凝基复合水凝对甲福明化药物的持续释放研究
Aleena Mir1, Wilbert J Fletcher2, Darlene K Taylor2
1Materials Research Laboratory, Department of Chemistry, Jamia Millia Islamia, New Delhi 110025, India.
ACS omega
|May 6, 2024
概括
这项研究合成了基于聚合物 (CP) 的导电复合水凝与凝用于药物输送. 这些新型水凝表现出受控释放动力学,为先进的治疗应用提供了潜力.
科学领域:
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
- 聚合物化学 聚合物化学
背景情况:
- 导电聚合物 (CPs) 为先进材料提供独特的电特性.
- 凝水凝是生物相容的,但往往缺乏可控释放能力.
- 结合CP和凝的复合水凝旨在提高药物输送性能.
研究的目的:
- 使用导电聚合物和凝 (GL-B) 合成和表征新型复合水凝.
- 评估这些水凝作为药物输送载体的潜力.
- 研究不同导电聚合物对水凝特性和药物释放动力学的影响.
主要方法:
- 用凝合成各种导电聚合物 (PNA,POPD,PANI,PVDF) 的复合水凝.
- 使用光谱,形态 (SEM) 和风湿学分析进行表征.
- 药物释放研究和运动模型 (零级,一级).
主要成果:
- 形态学研究证实了强烈的相互透的网络结构的形成.
- 风病学测量表明,根据使用的导电聚合物的类型,流动行为有所不同.
- 复合水凝的持续药物释放率约为10小时.
- 药物释放动力学最适合PNA,POPD和PANI基水凝的第一阶模型,以及PVDF/GL-B的零阶模型.
- 药物释放顺序是POPD/GL-B > PANI/GL-B > PVDF/GL-B. 药物释放顺序是POPD/GL-B > PANI/GL-B > PVDF/GL-B. 药物释放顺序是POPD/GL-B > PANI/GL-B > PVDF/GL-B. 药物释放顺序是POPD/GL-B. 药物释放顺序是POPD/GL-B.
结论:
- 以聚合物为基础的导电凝复合水凝成功合成和表征.
- 这些水凝具有可调节的特性和受控的药物释放配置文件.
- 这些发现表明,这些复合水凝在药物输送系统中具有有前途的应用.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
174
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
174
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
01:26Oral Drug Delivery Systems: Continuous-Release Systems
319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319